Dacarbazine
- Generic Name
- Dacarbazine
- Drug Type
- Small Molecule
- Chemical Formula
- C6H10N6O
- CAS Number
- 4342-03-4
- Unique Ingredient Identifier
- 7GR28W0FJI
- Background
An antineoplastic agent. It has significant activity against melanomas. (from Martindale, The Extra Pharmacopoeia, 31st ed, p564). Dacarbazine with Oblimersen is in clinical trials for the treatment of malignant melanoma.
- Indication
For the treatment of metastatic malignant melanoma. In addition, dacarbazine is also indicated for Hodgkin's disease as a secondary-line therapy when used in combination with other antineoplastic agents.
- Associated Conditions
- Advanced Pancreatic Neuroendocrine Tumors (pNET), Advanced Soft Tissue Sarcoma, Hodgkin's Lymphoma, Metastatic Melanoma, Pheochromocytoma, Advanced Medullary thyroid cancer
A Phase II Study of Sunitinib Versus Dacarbazine in the Treatment of Patients With Metastatic Uveal Melanoma
- First Posted Date
- 2012-03-12
- Last Posted Date
- 2019-10-29
- Target Recruit Count
- 124
- Registration Number
- NCT01551459
- Locations
- 🇬🇧
Clatterbridge Centre for Oncology NHS Foundation Trust, Wirral, United Kingdom
Metronomic Therapy in Patients With Metastatic Melanoma
- Conditions
- Metastatic Melanoma
- Interventions
- First Posted Date
- 2012-03-02
- Last Posted Date
- 2019-01-15
- Lead Sponsor
- Dartmouth-Hitchcock Medical Center
- Target Recruit Count
- 7
- Registration Number
- NCT01542255
- Locations
- 🇺🇸
Dartmouth-Hitchcock Medical Center, Lebanon, New Hampshire, United States
Brentuximab Vedotin and Combination Chemotherapy in Treating Older Patients With Previously Untreated Stage II-IV Hodgkin Lymphoma
- Conditions
- Adult Lymphocyte Depletion Hodgkin LymphomaAdult Lymphocyte Predominant Hodgkin LymphomaAdult Mixed Cellularity Hodgkin LymphomaAdult Nodular Sclerosis Hodgkin LymphomaStage II Adult Hodgkin LymphomaStage III Adult Hodgkin LymphomaStage IV Adult Hodgkin Lymphoma
- Interventions
- Procedure: quality-of-life assessmentGenetic: DNA analysisGenetic: RNA analysisRadiation: fludeoxyglucose F 18Procedure: positron emission tomographyOther: laboratory biomarker analysisOther: immunohistochemistry staining methodGenetic: polymorphism analysis
- First Posted Date
- 2011-11-22
- Last Posted Date
- 2020-02-17
- Lead Sponsor
- Northwestern University
- Target Recruit Count
- 48
- Registration Number
- NCT01476410
- Locations
- 🇺🇸
University of Chicago, Chicago, Illinois, United States
🇺🇸Stanford University Medical Center, Stanford, California, United States
🇺🇸Memorial Sloan- Kettering Cancer Center, New York, New York, United States
Prospective Study on HIV-related Hodgkin Lymphoma
- Conditions
- HIV-associated Hodgkin Lymphoma
- First Posted Date
- 2011-11-09
- Last Posted Date
- 2011-11-09
- Lead Sponsor
- Harlachinger Krebshilfe e.V.
- Target Recruit Count
- 130
- Registration Number
- NCT01468740
- Locations
- 🇩🇪
Infektionsmedizinisches Zentrum Hamburg, Hamburg, Germany
🇩🇪Vivantes Auguste Victoria Klinikum, Berlin, Germany
🇩🇪Ärzteforum Seestrasse, Berlin, Germany
Study of a-Interferon With Adriamycin, Bleomycin, Velban, and Dacarbazine (ABVD) With Hodgkin's Disease
- Conditions
- Lymphoma
- Interventions
- First Posted Date
- 2011-07-28
- Last Posted Date
- 2013-02-01
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 35
- Registration Number
- NCT01404936
- Locations
- 🇺🇸
UT MD Anderson Cancer Center, Houston, Texas, United States
Chemotherapy Based on PET Scan in Treating Patients With Stage I or Stage II Hodgkin Lymphoma
- Conditions
- Lymphoma
- Interventions
- First Posted Date
- 2011-07-11
- Last Posted Date
- 2023-06-29
- Lead Sponsor
- ECOG-ACRIN Cancer Research Group
- Target Recruit Count
- 6
- Registration Number
- NCT01390584
- Locations
- 🇺🇸
Stanford Cancer Center, Stanford, California, United States
🇺🇸McGlinn Family Regional Cancer Center at Reading Hospital and Medical Center, Reading, Pennsylvania, United States
Fotemustine and Dacarbazine Versus Dacarbazine +/- Alpha Interferon in Advanced Malignant Melanoma
- Conditions
- Malignant MelanomaRecurrent Melanoma
- Interventions
- First Posted Date
- 2011-05-25
- Last Posted Date
- 2023-04-11
- Lead Sponsor
- National Cancer Institute, Naples
- Target Recruit Count
- 269
- Registration Number
- NCT01359956
A Study of Trabectedin or Dacarbazine for the Treatment of Patients With Advanced Liposarcoma or Leiomyosarcoma
- Conditions
- Advanced Liposarcoma or Leiomyosarcoma
- Interventions
- First Posted Date
- 2011-04-28
- Last Posted Date
- 2016-08-26
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 579
- Registration Number
- NCT01343277
Phase 3 Study to Compare the Efficacy and Safety of Eribulin With Dacarbazine in Subjects With Soft Tissue Sarcoma
- Conditions
- Soft Tissue Sarcoma
- Interventions
- First Posted Date
- 2011-04-04
- Last Posted Date
- 2023-06-22
- Lead Sponsor
- Eisai Inc.
- Target Recruit Count
- 452
- Registration Number
- NCT01327885
Masitinib in Non-Resectable or Metastatic Stage 3/4 Melanoma Carrying a Mutation in the Juxta Membrane Domain of c-Kit
- First Posted Date
- 2011-01-21
- Last Posted Date
- 2020-11-05
- Lead Sponsor
- AB Science
- Target Recruit Count
- 134
- Registration Number
- NCT01280565
- Locations
- 🇺🇸
Blumenthal Cancer Centre, Charlotte, North Carolina, United States
🇫🇷Centre Hospitalier LE MANS, Le Mans, France
🇨🇿University Hospital Hradec Králové, Hradec Králové, Czechia
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.